ArticleScientific reports2023
Distribution of bla
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Pooled it
- Quinolone resistance of Pseudomonas aeruginosa isolated from hospital infections and MexAB-OprM efflux pumps.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Occurrence and Distribution of Environmental Pseudomonas aeruginosa From Hospitals in Bangladesh Reveals Diverse Strain Families, Multidrug Resistance, and Biofilm Formation.Environmental microbiology reports · 2026Article
- Phenotypic and genotypic antimicrobial resistance profiles of gram-positive cocci and non-fermenting gram-negative rods.Scientific reports · 2026Article
- Prevalence and associated risk factors of Pseudomonas aeruginosa infection in Diabetic wounds in Duhok province, Iraq.PloS one · 2026Article
- Genetic study of extended spectrum beta-lactamase genes; bla-TEM, blaOXA-10, blaSHV and per-1 in pseudomonas aeruginosa from hospital-acquired infections.Antonie van Leeuwenhoek · 2025Article
- Antimicrobial resistance profile, biofilm forming capacity and associated factors of multidrug resistance in Pseudomonas aeruginosa among patients admitted at Tikur Anbessa Specialized Hospital and Yekatit 12 Hospital Medical College in Addis Ababa, Ethiopia.BMC infectious diseases · 2024Article
- Structural insights into alterations in the substrate spectrum of serine-β-lactamase OXA-10 fromEmerging microbes & infections · 2024Article
- Outbreak ofAntibiotics (Basel, Switzerland) · 2024Article
- Model-based optimization of controlled release formulation of levodopa for Parkinson's disease.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pseudomonas aeruginosa is resistant to a wide range of extended spectrum-lactamases (ESBLs) antibiotics because it produces several kinds of ESBLs. The goal of the current investigation was to identify the bacteria that produce extended spectrum -lactamases and the genes that encode three different ESBLs, such as bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.